Market Outlook Snapshot Market Dynamics Regional Forecast Country Insights Segment Analysis Competitive Landscape Industry News report.faq_name
On This Report

Network Point-of-Care Glucose Testing Market Size & Growth Forecast 2026–2035, By Segments (Product), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Report ID: FBI 12533| Published Date: Apr-2026| Format: PDF, Excel
MARKET OUTLOOK

Market Size and Growoth Outlook

Network Point-of-Care Glucose Testing Market size was worth USD 1.43 Billion in 2025 and is expected to grow at a 4.5% CAGR between 2026 and 2035, exceeding USD 2.22 Billion by 2035. The industry revenue for 2026 is estimated at USD 1.48 billion.

Base Year Value (2025)
USD 1.43 Billion
CAGR (2026-2035)
4.5%
Forecast Year Value (2035)
USD 2.22 Billion
Historical Data Period
2022-2025
Largest Region
North America
Forecast Period
2026-2035

Get more details on this report

Request Free Sample Report
SNAPSHOT

Network Point-of-Care Glucose Testing Market Intelligence Snapshot

Regional Market Dynamics

  • North America leads with 43.14% share due to advanced digital health infrastructure, widespread hospital adoption, and strong integration of glucose testing devices with electronic medical records.
  • Asia Pacific is growing at 5.13% CAGR driven by healthcare modernization, expanding hospital networks, and increasing adoption of connected point-of-care testing systems for faster clinical decision-making.

Segment Momentum

  • Accu-Chek Inform II leads the market because its established use in hospital and clinical workflows delivers reliable connectivity, standardized operation, and smooth integration into networked point-of-care testing environments.
  • CareSens Expert Plus is growing fastest as healthcare providers increasingly prioritize workflow flexibility, connected testing efficiency, and easy integration into digitally managed point-of-care testing processes.

Market Expansion Drivers

  • Rising diabetes prevalence driving demand for rapid decentralized glucose monitoring solutions.
  • Increasing adoption of remote patient monitoring systems improving real-time diabetes management outcomes.
  • Expansion of digital health infrastructure enabling connected diagnostic device integration across care networks.

Leading Market Participants

FORECAST SNAPSHOT

Global Market Forecast Snapshot

Market Outlook

Key companies in the network point-of-care glucose testing market include Abbott Laboratories (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Nova Biomedical Corporation (United States), Ascensia Diabetes Care Holdings AG (Switzerland), Nipro Corporation (Japan), ACON Laboratories, Inc. (United States), Prodigy Diabetes Care, LLC (United States), Siemens Healthineers AG (Germany), LifeScan, Inc. (United States).

Regional and Segment Outlook

North America
MARKET DYNAMICS

Market Growth Drivers and Industry Trends

Rising diabetes prevalence driving demand for rapid decentralized glucose monitoring solutions

As diabetes case volumes rise, providers are under pressure to monitor larger patient populations without relying exclusively on central laboratory workflows, which pushes purchasing toward faster bedside and near-patient testing formats. In the network point-of-care glucose testing market, This transitions demand toward connected glucose meters that can deliver immediate readings in hospitals, outpatient clinics, long-term care settings, and emergency departments while automatically transmitting results into clinical systems. The practical effect is stronger instrument placement and recurring consumables use, as care teams prioritize rapid triage, insulin dosing support, and tighter glucose surveillance for a broader mix of routine and high-risk patients.

Increasing adoption of remote patient monitoring systems improving real-time diabetes management outcomes

Remote patient monitoring is changing how diabetes is managed by making glucose data part of an ongoing clinical feedback loop rather than a series of isolated in-person measurements. For the network point-of-care glucose testing market, this supports market expansion by increasing the value of devices that can transmit accurate readings to clinicians, care coordinators, and digital platforms in near real time. Health systems and provider groups are more likely to favor networked testing solutions when those devices help identify excursions earlier, inform medication adjustments between visits, and reduce delays in intervention, especially for patients requiring closer supervision after discharge or in home-based care pathways.

Expansion of digital health infrastructure enabling connected diagnostic device integration across care networks

As healthcare organizations invest in interoperable records, wireless connectivity, cloud-based data management, and device integration platforms, connected glucose testing becomes easier to deploy at scale rather than site by site. This is driving market development in the network point-of-care glucose testing market because buyers increasingly evaluate glucose meters not only on analytical performance but on how reliably they connect with electronic health records, middleware, and enterprise quality management systems. Integration reduces manual transcription, supports centralized oversight of operator compliance and device status, and gives multi-site providers a clearer operational case for standardizing on network-enabled point-of-care testing platforms.

Growth Driver Impact on CAGR Regulatory Influence Geographic Relevance Adoption Rate Impact Timeline
Rising diabetes prevalence driving demand for rapid decentralized glucose monitoring solutions 2.00% High Asia Pacific, Middle East & Africa High Near Term
Increasing adoption of remote patient monitoring systems improving real-time diabetes management outcomes 1.80% High North America, Europe High Mid Term
Expansion of digital health infrastructure enabling connected diagnostic device integration across care networks 1.50% Moderate North America, Asia Pacific Emerging Long Term
CUSTOM RESEARCH

Unlock insights tailored to your business with our bespoke market research solutions.

Click to get your customized report now.

Request Customization →
REGIONAL FORECAST

Regional Demand Dynamics

Polymer Modified Bitumen Market
Largest Region
North America
43.14% Market Share in 2025
North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held a 43.14% share of the network point-of-care glucose testing market in 2025, supported by the region’s broad installed base of connected diagnostic systems across hospitals, clinics, and integrated care networks. Its leadership is strengthened by established digital health infrastructure, routine use of bedside glucose monitoring in acute care settings, and stronger interoperability between testing devices and electronic medical record platforms, which helps providers manage patient data more efficiently and sustain high testing volumes in day-to-day clinical practice.

Asia Pacific is projected to expand at a 5.13% CAGR over the forecast period in the network point-of-care glucose testing market, driven by the ongoing modernization of healthcare delivery and wider adoption of decentralized testing workflows. Growth is being propelled by increasing deployment of connected diagnostic equipment in hospitals and outpatient settings, where providers are placing greater emphasis on faster result access, more streamlined data transfer, and improved monitoring efficiency as healthcare systems scale capacity and digital connectivity.

Parameter North America Asia Pacific Europe Latin America MEA
Innovation Hub i Scale Nascent Developing Advanced
Cost-Sensitive Region i Scale Low Medium High
Regulatory Environment i Scale Restrictive Neutral Supportive
Demand Drivers i Scale Weak Moderate Strong
Development Stage i Scale Emerging Developing Developed
Adoption Rate i Scale Low Medium High
New Entrants / Startups i Scale Sparse Moderate Dense
Macro Indicators i Scale Weak Stable Strong
COUNTRY INSIGHTS

Key Country Insights

Germany 🇩🇪

Digitized clinical integration

In Germany, adoption of network point-of-care glucose testing is shaped by structured healthcare systems prioritizing interoperability with hospital IT infrastructure. Clinical users in Germany focus on standardized data transmission and accuracy, particularly in diabetes management programs across outpatient and hospital-linked care pathways.

France 🇫🇷

Structured diabetes pathways

In France, network point-of-care glucose testing is increasingly embedded in structured diabetes care pathways across primary and specialist settings. Healthcare facilities in France prioritize system compatibility and reliable data capture to support coordinated long-term patient monitoring.

Italy 🇮🇹

Primary care modernization

In Italy, expansion of point-of-care glucose testing networks is linked to modernization of primary care services and chronic disease monitoring. Healthcare providers in Italy focus on cost-efficient, connected systems that improve workflow efficiency in outpatient diabetes management.

Japan 🇯🇵

Aging care monitoring systems

In Japan, demand is driven by aging population care models where networked glucose testing supports frequent monitoring in clinics and eldercare settings. Healthcare providers in Japan prioritize compact, reliable devices with seamless connectivity to centralized patient management platforms.

South Korea 🇰🇷

Smart clinic connectivity

In South Korea, rapid digitization of healthcare services is supporting wider use of connected point-of-care glucose testing in clinics and community health centers. Providers in South Korea emphasize real-time data transfer and integration with digital health platforms for improved chronic disease management efficiency.

United States 🇺🇸

Distributed chronic care adoption

In the U.S., network-enabled point-of-care glucose testing is increasingly integrated into primary care and diabetes management programs, supporting decentralized monitoring across clinics and home-linked care networks. Providers in the U.S. emphasize connectivity with electronic health records and streamlined data sharing for continuous patient oversight.

SEGMENT ANALYSIS

Segment Leadership and Growth Trends

Network Point-of-Care Glucose Testing Market Share (%), Product, 2025

Accu-Chek Inform II
StatStrip
i-STAT
HemoCue
CareSens Expert Plus
BAROzen H Expert Plus

Go beyond the chart, access full insights & data tables

Request Free Sample Report
Product Segment Analysis: Accu-Chek Inform II (Largest Segment) vs CareSens Expert Plus (Fastest-Growing Segment)

Within the network point-of-care glucose testing market, Accu-Chek Inform II held the largest share in 2025, backed by its established presence in hospital and clinical testing workflows where connectivity, reliability, and standardized operation are central to routine glucose monitoring. its position is underpinned by the practical preference of care settings for systems already embedded in networked environments, since consistency in device performance and smoother integration with point-of-care management processes reduce operational disruption and support broad user adoption.

CareSens Expert Plus is emerging as the fastest-growing product in the network point-of-care glucose testing market as buyers increasingly weigh workflow flexibility and connected testing efficiency when evaluating newer device deployments. Its momentum is being influenced by demand for solutions that align with evolving point-of-care requirements in decentralized care environments, where ease of use and fit within digitally managed testing processes can accelerate uptake relative to more established alternatives.

Segment Sub-Segment Largest Segment Fastest Growing
Product i-STAT, Accu-Chek Inform II, StatStrip, HemoCue, CareSens Expert Plus, BAROzen H Expert Plus Accu-Chek Inform II CareSens Expert Plus
Competitive Landscape

Competitive Landscape and Market Positioning

Key companies in the network point-of-care glucose testing market:

1. Abbott Laboratories (United States)

2. F. Hoffmann-La Roche Ltd. (Switzerland)

3. Nova Biomedical Corporation (United States)

4. Ascensia Diabetes Care Holdings AG (Switzerland)

5. Nipro Corporation (Japan)

6. ACON Laboratories Inc. (United States)

7. Prodigy Diabetes Care LLC (United States)

8. Siemens Healthineers AG (Germany)

9. LifeScan Inc. (United States)

The network point-of-care glucose testing market is evolving through digital integration that enhances real-time diagnostic connectivity and patient monitoring. Expansion into emerging healthcare settings is broadening accessibility of testing solutions. Research advancements are improving accuracy, speed, and usability of glucose testing systems.

Company Market Share Company Revenue Revenue CAGR (%) Product Portfolio Geographic Presence Innovation / R&D Focus Strategic Developments
No companies available.
🔒 This section is available as a standalone purchase. Buy only the data you need. Inquire Before Buying
Industry News

Industry Development/News

Company Name Date Key Development
Abbott Laboratories Jun-24 Abbott Laboratories received FDA clearance for Libre Rio and Lingo over-the-counter glucose monitoring devices. Libre Rio targets type 2 diabetes patients not using insulin, while Lingo provides continuous glucose tracking with personalized metabolic insights, expanding access to consumer-focused glucose monitoring solutions.
Nova Biomedical Mar-24 Nova Biomedical launched its next-generation StatStrip Glucose Hospital Meter System with FDA 510(k) clearance. The system introduces enhanced cybersecurity, RFID-enabled data entry, wireless charging, and ruggedized design to improve accuracy, connectivity, and operational reliability in critical care glucose testing environments.
Glooko Jun-26 Glooko introduced an insulin pump settings EHR integration enabling device-agnostic visualization of basal rates and insulin-to-carbohydrate ratios directly within electronic health record systems. The solution enhances clinical decision-making by improving interoperability between diabetes devices and hospital data infrastructure.
Abbott May-26 Abbott received CE Mark approval for Libre Duo and Libre Duo 10 Day, dual glucose-ketone biowearable sensors capable of continuous monitoring of both biomarkers from a single device. The approval expands Abbott’s multi-analyte monitoring capabilities in the European diabetes management market.
Glooko May-26 Glooko obtained FDA 510(k) clearance for EndoTool IV Cloud, a cloud-based insulin dosing platform designed for hospital use. The solution supports automated insulin management workflows and strengthens digital therapeutics integration within inpatient diabetes care settings.
Trividia Health Feb-26 Trividia Health issued a Class I recall for TRUE METRIX Blood Glucose Monitoring Systems due to an E-5 error code labeling issue. The recall impacts multiple regions and reflects regulatory action to ensure accuracy and safety in point-of-care glucose monitoring devices.
Ascensia Diabetes Care Jan-26 Ascensia Diabetes Care transferred Eversense CGM commercialization rights to Senseonics, completing the U.S. transition in January 2026 with European transition expected by June 2026. The restructuring shifts commercial responsibilities for continuous glucose monitoring devices within the diabetes technology ecosystem.
Abbott Laboratories Jun-24 Abbott Laboratories expanded its glucose monitoring portfolio with FDA-cleared consumer-oriented devices designed to extend continuous glucose monitoring beyond insulin-dependent patients. The development supports broader adoption of real-time metabolic health tracking in preventive and lifestyle healthcare segments.
Abbott Laboratories Jun-24 Received FDA clearance for Libre Rio and Lingo over-the-counter glucose monitoring devices. Libre Rio is targeted at type 2 diabetes patients not using insulin, while Lingo provides continuous glucose tracking with personalized insights, expanding consumer-accessible glucose monitoring within the point-of-care ecosystem.
Nova Biomedical Mar-24 Launched the StatStrip Glucose Hospital Meter System with FDA 510(k) clearance, featuring enhanced cybersecurity, wireless charging, RFID-enabled data entry, and ruggedized design to improve accuracy and secure glucose testing in critical care hospital environments.
Meta Jun-25 Introduced generative AI video editing capabilities across Meta AI app and related platforms, enabling transformation of video content using AI prompts for style, setting, lighting, and narrative effects, supporting broader AI-driven content creation workflows.
Cartwheel May-25 Launched a 3D animation AI tool suite that converts video, text, and motion libraries into production-ready 3D animations, enabling streamlined editing and integration into film, gaming, advertising, and digital content pipelines.
Google LLC May-24 Introduced AI-powered advertising and search enhancements, including generative search experiences and tools enabling advertisers to create animated ads from still images with customizable branding elements for improved engagement and personalization.
Autodesk May-24 Acquired Wonder Dynamics to integrate AI-enabled cloud-based 3D animation and VFX tools into its production ecosystem, strengthening end-to-end digital content creation capabilities across media and entertainment workflows.
Kartoon Studios, Inc. Apr-24 Launched an AI-powered animation toolkit designed to improve production efficiency and content quality by integrating generative AI into animation workflows for enhanced creative output and streamlined studio operations.
Glooko Jun-26 Introduced insulin pump settings EHR integration enabling visualization of device-agnostic insulin pump data within electronic health record systems, improving clinical decision-making through consolidated digital diabetes management data.
Abbott May-26 Received CE Mark approval for Libre Duo and Libre Duo 10 Day, dual glucose-ketone biowearable devices enabling simultaneous continuous monitoring of glucose and ketones from a single sensor platform.
Glooko May-26 Obtained FDA 510(k) clearance for EndoTool IV Cloud, a cloud-based insulin dosing platform for hospital use, expanding digital therapeutics capabilities for inpatient glycemic management.
Trividia Health Feb-26 Issued a Class I recall of TRUE METRIX Blood Glucose Monitoring Systems due to labeling-related E-5 error code issues, impacting multiple regional markets and requiring corrective quality and compliance actions.
Ascensia Diabetes Care Jan-26 Entered agreement to transfer Eversense CGM commercialization rights to Senseonics, with U.S. transition completed in January 2026 and European transition expected by June 2026, restructuring its CGM commercialization footprint.
Report Customization

Explore This Report

Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.

1 report.custom report.segments 2 Custom TOC 3 Related Reports

Network Point-of-Care Glucose Testing Market — Custom Segments

Segment Sub-Segment
No segment data available.

Network Point-of-Care Glucose Testing Market — report.custom

Custom Chapter Custom Details
No custom TOC data available.

Need a different cut of the data?

Request Custom Research
report.faq_name

How large is the network point-of-care glucose testing market?

The market revenue for network point-of-care glucose testing is anticipated at USD 1.48 billion in 2026.

What is the expected industry size of network point-of-care glucose testing by 2035?

Network Point-of-Care Glucose Testing Market size is estimated to increase from USD 1.43 billion in 2025 to USD 2.22 billion by 2035 supported by a CAGR exceeding 4.5% during 2026-2035.

How is rising diabetes prevalence shaping demand for networked point-of-care glucose testing solutions?

Growing patient volumes are driving adoption of connected bedside glucose meters that deliver rapid readings and integrate directly into clinical systems, supporting faster triage, insulin dosing decisions, and broader decentralized monitoring across care settings.

Why is digital health infrastructure critical to scaling connected glucose testing across healthcare networks?

Interoperable records and wireless connectivity enable seamless device integration with EHRs and middleware, reducing manual entry and supporting centralized oversight, making networked glucose testing easier to standardize across multi-site healthcare systems.

Why is Accu-Chek Inform II the leading product in the network point-of-care glucose testing market?

Accu-Chek Inform II leads the market because its established use in hospital and clinical workflows delivers reliable connectivity, standardized operation, and smooth integration into networked point-of-care testing environments.

Why is CareSens Expert Plus the fastest-growing product in the network point-of-care glucose testing market?

CareSens Expert Plus is growing fastest as healthcare providers increasingly prioritize workflow flexibility, connected testing efficiency, and easy integration into digitally managed point-of-care testing processes.

Why does North America lead the network point-of-care glucose testing market?

North America leads with 43.14% share due to advanced digital health infrastructure, widespread hospital adoption, and strong integration of glucose testing devices with electronic medical records.

What is driving Asia Pacific’s growth in this market?

Asia Pacific is growing at 5.13% CAGR driven by healthcare modernization, expanding hospital networks, and increasing adoption of connected point-of-care testing systems for faster clinical decision-making.

Who holds a significant market share in the network point-of-care glucose testing landscape?

Key companies in the network point-of-care glucose testing market include Abbott Laboratories (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Nova Biomedical Corporation (United States), Ascensia Diabetes Care Holdings AG (Switzerland), Nipro Corporation (Japan), ACON Laboratories, Inc. (United States), Prodigy Diabetes Care, LLC (United States), Siemens Healthineers AG (Germany), LifeScan, Inc. (United States).
Testimonials

Our Clients

"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."

Quality Assurance Manager

"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."

R&D Manager

"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."

Senior Marketing Manager
THE RESEARCH BEHIND THIS REPORT

Our Research Team & Methodology

Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.

THIS REPORT'S RESEARCH VERTICAL

Research Team Overview

♢
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.

Prepared by the Healthcare & Medical Devices Research Team

10+
Industry Verticals
100+
Countries Analyzed
5–7
Days Standard
Delivery
12k+
Research Reports
Published
On-
Demand
Customized Research
Available
6
Months Analyst
Support
PDF + XLS
Report Deliverables

Trust & Compliance

☷D&B D-U-N-S
♢GDPR & CCPA Compliant
♙ISO 9001 Certified (ISO 9001:2015)
♙SSL Encryption
▭Secure Payments
✓Confidential Handling

Research Domains

10 coverage areas
Medical Devices & Equipment Diagnostic Imaging Clinical Diagnostics Digital Health & Telemedicine Patient Monitoring Systems Surgical & Minimally Invasive Technologies Healthcare IT & Data Systems Biotechnology & Life Sciences Pharmaceutical Technologies Healthcare Delivery & Services

Research Intelligence

Executive Leadership
Product & Technology Experts
Manufacturing & Operations Leaders
Procurement & Supply Chain Professionals
Sales & Commercial Executives
Channel Partners & Distribution Networks
Enterprise Buyers & End Users
Industry Consultants & Regulatory Experts

Research Workflow & Quality Assurance

📥
01

Data Collection

Verified information gathered through primary and secondary research.

🔍
02

Data Triangulation

Cross-validation using multiple independent data sources.

📈
03

Forecast Modelling

Market estimates developed using historical trends and analytical models.

👨‍💼
04

Analyst Validation

Findings reviewed by domain experts for accuracy and consistency.

📝
05

Editorial & Quality Review

Final editorial, quality, and compliance checks before publication.

✅
06

Final Publication

Released after successful completion of the internal review process.

Report Coverage

📊 Market Assessment

  • Market Size & Forecast
  • Market Segmentation
  • Regional Analysis
  • Growth Drivers & Challenges
  • Market Dynamics

🏢 Competitive Intelligence

  • Competitive Landscape
  • Company Profiles
  • Competitive Benchmarking
  • Mergers & Acquisitions
  • Market Share Analysis or Key Company Strategies

🔍 Strategic Analysis

  • Value Chain Analysis
  • Porter's Five Forces
  • PESTLE Analysis
  • Pricing Trends
  • Supply-Demand Analysis

🚀 Future Outlook

  • Technology Landscape
  • Regulatory Landscape
  • Investment & Funding Landscape
  • Emerging Opportunities
  • Future Market Outlook

Have a question about this report or need a custom scope?

Request Customization
License

Select License Type

Single User
US$ 4,250
Buy Now
Corporate User
US$ 6,150
Buy Now

Want this data scoped to your exact question?

Tell us the segments, regions, or competitors you need answered — an analyst will confirm scope before any custom work starts.

Talk to an Analyst →